Creative Planning
ADCT icon

Creative Planning’s ADC Therapeutics ADCT Stock Holding History

Creative Planning’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7K Sell
24,032
-55,002
-70% -$160K ﹤0.01% 4175
2026
Q1 		$296K Sell
79,034
-34,213
-30% -$135K ﹤0.01% 3435
2025
Q4 		$400K Buy
113,247
+6,596
+6% +$26.8K ﹤0.01% 3029
2025
Q3 		$427K Buy
106,651
+70,652
+196% +$223K ﹤0.01% 2857
2025
Q2 		$96.5K Buy
+35,999
New +$75.7K ﹤0.01% 3437
2025
Q1 		– Sell
-475
Closed -$945 – 3460
2024
Q4 		$945 Buy
+475
New +$1.24K ﹤0.01% 3527

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Planning's ADCT Position: Q2 2026 in Review

Creative Planning reduced its ADC Therapeutics (ADCT) stake by 70% in Q2 2026, selling an estimated $160K and leaving 24,032 shares worth $25.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4175.

Creative Planning first reported a position in ADCT in Q4 2024 and has held it in 6 quarters since. The position peaked at $427K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Creative Planning held 24,032 shares of ADC Therapeutics worth $25.7K as of Q2 2026.
  • Creative Planning sold 55,002 ADC Therapeutics shares in Q2 2026, an estimated $160K.
  • ADC Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4175 holding.
  • Creative Planning first reported a position in ADC Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Creative Planning's ADC Therapeutics position peaked at $427K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.